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Abstract Elevated islet uncoupling protein-2 (UCP-2) impairs
L-cell function and UCP-2 may be increased in clinical obesity
and diabetes. We investigated the effects of glucose and leptin on
UCP-2 expression in isolated human islets. Human islets were
incubated for 24 h with glucose (5.5^22 mmol/l) þ leptin (0^10
nmol/l). Some islet batches were incubated at high (22 mmol/l),
and subsequently lower (5.5 mmol/l), glucose to assess reversi-
bility of effects. Leptin effects on insulin release were also
measured. Glucose dose-dependently increased UCP-2 expres-
sion in all islet batches, maximally by three-fold. This was not
fully reversed by subsequently reduced glucose levels. Leptin
decreased UCP-2 expression by up to 75%, and maximally
inhibited insulin release by 47%, at 22 mmol/l glucose. This is the
first report of UCP-2 expression in human islets and provides
novel evidence of its role in the loss of L-cell function in
diabetes. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Uncoupling protein-2 (UCP-2) is a homologue of UCP-1, a
thermogenic mitochondrial protein expressed primarily in
brown adipose tissue which uncouples respiration from ATP
generation, and is expressed in many tissues including pancre-
atic islets [1]. Over-expression of UCP-2 in rat islets results in
impaired glucose-stimulated insulin secretion (GSIS) [2]. Lep-
tin has been shown to increase UCP-2 expression in rat islets
[1] and this has been suggested as a possible mechanism for
leptin’s direct inhibition of insulin secretion, a phenomenon
that has been observed in several studies [3,4] although a few
have demonstrated stimulatory [5] or nil [6] e¡ects of the
hormone. It has been suggested [2] that UCP-2 decreases
GSIS because it would be expected to reduce the cellular
ATP/ADP ratio as a result of its proposed uncoupling proper-
ties. This would in turn reduce the capacity of increased glu-
cose concentrations to stimulate insulin release through clo-
sure of the KATP channel.
In the present study we examined the e¡ect of glucose and
leptin on UCP-2 mRNA expression and insulin secretion in
human islets. Initial studies (previously reported in brief [7])
provided a serendipitous indication that glucose alone is ca-
pable of increasing UCP-2 expression and we therefore
studied this dose related e¡ect which could provide an expla-
nation for so-called glucose toxicity.
2. Materials and methods
2.1. Insulin release from human islets
Human islets isolated from pancreases of heart-beating donors,
under both multi-centre and local ethical committee consents, were
obtained from the islet transplant programmes at Leicester Royal
In¢rmary (UK) (batches designated HP) and Worcester Royal In¢r-
mary (UK) (batches designated W). Islets were cultured in 24-well
plates (100 islet equivalents (IE) per well), in RPMI 1640 medium
containing 5.5 mmol/l D-glucose, 10% foetal bovine serum, 50 U/ml
penicillin, 50 Wg/ml streptomycin and 2 mmol/l L-glutamine, and al-
lowed to attach for 48 h before treatments. Islets were then subse-
quently incubated in serum-free RPMI medium containing glucose
(5.5, 11 or 22 mmol/l) and leptin (0, 0.1, 1, 5 and 10 nmol/l) for 20
h. Samples were collected, centrifuged at 500Ug for 5 min to remove
loose cells and assayed for insulin by standard radioimmunoassay.
2.2. UCP-2 mRNA expression
2.2.1. Incubations. Human islets from ¢ve di¡erent donors were
incubated at 1000 IE/well in 6-well plates containing serum-free RPMI
medium containing 5.5, 11 or 22 mmol/l glucose (G) for 24 h (in the
case of two donors the 11 mmol/l G treatment was omitted because of
limited islet availability). In a further series of experiments (‘reversi-
bility protocol’), islets from two separate donors were treated as be-
fore with the following modi¢cations: (1) 5.5 mmol/l G, 24 h; (2) 22
mmol/l G, 24 h; (3) 5.5 mmol/l G 48 h; (4) 22 mmol/l G 48 h; (5) 22
mmol/l G 24 h followed by 24 h 5 mmol/l G.
2.2.2. RT-PCR. Total RNA from treated islets was extracted us-
ing a modi¢ed guanidinium thiocyanate^phenol method (TRIzol re-
agent; Sigma, Poole, Dorset, UK) and mRNA levels were quanti¢ed
using a semi-quantitative RT-PCR method using oligo(dT)15 primers
and AMV reverse transcriptase (Hybaid, UK) for reverse transcrip-
tion, and sequence-speci¢c primers for UCP-2 (sense primer
TCTGACCATGGTGCGTACTGA; antisense primer GACAATGG-
CATTACGAGCAAC) and the housekeeping gene L-actin (sense
primer CGGGAAATCGTCGTGCGTGACAT; antisense primer
GAACTTTGGGGGATGCTCGC) for cDNA ampli¢cation (using
an annealing temperature of 60‡C for 36 cycles). PCR products
were electrophoresed through 2% agarose gel, stained with ethidium
bromide and visualised under ultraviolet illumination. Band intensity
was calculated densitometrically using SCION imaging software
(NIH).
2.3. Statistical analysis
Comparisons between single pairs of data were made using Stu-
dent’s t-test for paired data. Multiple comparisons were made by
one-way ANOVA with Dunnett’s post-hoc analysis. In all cases
P9 0.05 was taken as signi¢cant.
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3. Results
3.1. E¡ect of leptin on insulin release
Leptin had no signi¢cant e¡ect on insulin release at low (5.5
mmol/l) or moderate (11 mmol/l) glucose concentrations on
any of the batches of islets tested (results not shown). At high
glucose levels leptin had a U-shaped e¡ect in one batch of
islets (with a signi¢cant maximal inhibition at 0.1 nmol/l lep-
tin of 69%) but caused a dose-related inhibition in other
batches (signi¢cant maximal inhibition at 5^10 nmol/l of 46^
56%) (Fig. 1).
3.2. E¡ects of leptin on UCP-2 expression
In this series of experiments it was observed that there was
comparatively little UCP-2 expression at low (5.5 mmol/l)
glucose whereas at high (22 mmol/l) glucose there was a
three-fold higher level of UCP-2 mRNA (Fig. 2). Leptin
had no e¡ect on UCP-2 expression at low glucose concentra-
tions (results not shown). At high glucose concentrations,
however, leptin induced a general dose-dependent reduction
in UCP-2 mRNA expression from the high levels observed
with 22 mmol/l glucose alone, although with some islet
batches an initial stimulation was observed at the lowest
(1.6 ng/ml) concentrations of leptin (Fig. 2).
3.3. E¡ect of glucose on UCP-2 expression
Further studies, initiated following the above observation
that UCP-2 expression appeared to be higher in islets exposed
to high glucose, demonstrated over several islet batches that
this was a highly consistent e¡ect. In all batches UCP-2
mRNA expression was dose-dependently increased by expo-
sure to elevated glucose concentrations (Fig. 3). The threshold
concentration at which this occurred varied between batches
(e.g. expression appeared maximal at 11 mmol/l in HP614, but
the e¡ect was still increasing at this glucose concentration in
other batches (HP602 and HP617)). The maximal increase
was approximately three-fold (P = 0.027).
3.4. Reversibility of UCP-2 mRNA increase
Islets incubated in 22 mmol/l glucose for 24 h and then for
a further 24 h at 5.5 mmol/l glucose still exhibit elevated levels
of UCP-2 mRNA when compared with those incubated for
the whole 48 h in 5.5 mmol/l, although the level is lower than
that observed in islets incubated for 48 h in 22 mmol/l glucose
(Fig. 4).
4. Discussion
This is the ¢rst report of UCP-2 expression in human islets.
In addition this is the ¢rst study to demonstrate the novel
¢nding that exposure to hyperglycaemic environments results
in increased expression of UCP-2, although a recent prelimi-
nary report has described similar ¢ndings in rat islets [8].
Given that human islets are notoriously variable due to the
wide variation in donor characteristics (e.g. age, disease, met-
abolic status, cause of death) the e¡ect appears to be impres-
sively consistent, occurring in all seven batches tested. Whilst
the mechanism of glucose induction of UCP-2 is unclear as
yet, the e¡ect suggests a possible mechanism whereby the
Fig. 1. Leptin inhibits insulin release from human islets. Recombi-
nant human leptin caused a dose-dependent decrease in insulin re-
lease from human islets over 20 h. a: One batch (W100) exhibited a
U-shaped response to leptin. b: Another three batches (representa-
tive sample batch HP598 shown) gave a linear reduction. Data ex-
pressed as means þ S.E.M., n = 6^12; *signi¢cant compared to con-
trol (0 leptin) P6 0.05 by ANOVA/Dunnett’s post-hoc analysis.
Fig. 2. Leptin inhibits UCP-2 mRNA expression induced by high
glucose. Leptin caused a dose-dependent inhibition of UCP-2
mRNA expression which was elevated at 22 mmol/l glucose. Data
shown are a representative sample from three sets of similar data
obtained from di¡erent batches of human islets.
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phenomenon of ‘glucose toxicity’ could occur. Prolonged ex-
posure to high concentrations of glucose has been observed to
impair GSIS in vivo (e.g. [9]) and in vitro (e.g. [10]). The work
of Chan et al. [2,11] showing that over-expression of UCP-2 in
rat islets causes impairment of GSIS coupled with the present
¢ndings would imply that glucose exposure causes an increase
in UCP-2 expression which in turn impairs GSIS. UCP-2 is
likely, by means of its probable ability to uncouple ATP pro-
duction from respiration, to reduce cellular ATP/ADP ratios
leading to a greater opening of KATP channels and thus re-
duced insulin secretion.
UCP-2 has also been reported to have pro-apoptotic prop-
erties ([12], also G. Williams (Keele University, UK), personal
communication); the recent report that high glucose induces
apoptosis in human islets [13] lends support to our suggestion
that UCP-2 might have a role in this process. The possible
uncoupling role of UCP-2 is controversial : the protein has
been reported to cause proton leakage in transfected yeast
[14] but it has been suggested that this is an artefact not
observed with physiological levels of UCP-2 [15]. Chan et
al. [11] have demonstrated however that, when over-expressed
by adenovirus methodology, UCP-2 does lower mitochondrial
membrane proton gradients and reduce ATP/ADP ratios. A
recent report from the group of Lowell [16] con¢rms that
UCP-2 knock-out mice have raised islet ATP and increased
GSIS. Interestingly, the same study also demonstrated an in-
crease in UCP-2 levels in leptin-de¢cient ob/ob mice; this is
consistent with our ¢nding that leptin prevents high glucose
elevation of UCP-2 since in the absence of leptin this e¡ect of
hyperglycaemia would not be inhibited.
The role of UCP-2 as a modulator of GSIS is becoming
increasingly apparent; a recent study suggested that exposure
of rat islets to elevated non-esteri¢ed fatty acids, known to
have both long-term (inhibitory) and short-term (stimulatory)
e¡ects on GSIS, increased UCP-2 protein expression [17].
Other reports have suggested that UCP-2 may have a protec-
tive function against glucotoxicity since it might be expected
to reduce levels of reactive oxygen species in the cells [18].
It is signi¢cant that the increase in UCP-2 does not appear
to be wholly reversible within 24 h, and this would imply that
the high glucose induction of UCP-2 expression and conse-
quent impairment of GSIS may be a persistent e¡ect. In order
to provide support for our hypothesis, future work will need
to focus on levels of UCP-2 protein following hyperglycaemic
conditions using, for example, Western blotting and immuno-
histochemistry.
The ¢nding that leptin inhibits insulin secretion is consistent
with most previous studies (e.g. [3,4]), but not all [5,6]. The U-
shaped response observed in one batch of islets is interesting
and has also been reported in rat islets [19] : it is possible that
this phenomenon would have been observed in other batches
had the dose range been extended since human islets are likely
to vary considerably in their dose response given the varia-
bility of donor previously referred to. Such a U-shaped re-
sponse could explain the variability of leptin’s e¡ects reported
in the literature. One possible explanation could lie in the
cytokine-like nature of leptin’s interaction with its receptor
which requires homo-oligomerisation of the receptor by its
ligand for activation of the JAK/STAT signalling pathway
(discussed in review [20]). High leptin levels could saturate
the receptor, preventing homo-oligomerisation.
Our data showing suppression of UCP-2 by leptin are at
variance with those obtained by Unger and co-workers [1]
who found that leptin increased UCP-2 mRNA. There were
a number of di¡erences in the experimental approaches how-
ever, since we used human, rather than rodent, islets and we
observed the suppressive e¡ect at high glucose concentrations.
The present ¢ndings do not support the suggestion that leptin
may inhibit insulin release and contribute to the pathogenesis
of type 2 diabetes by increasing UCP-2.
In conclusion, we have demonstrated a highly reproducible
e¡ect of high glucose on UCP-2 gene expression which, in
conjunction with the increasing body of published data sug-
gesting a role for UCP-2 in modulation of glucose-stimulated
insulin secretion and possibly L-cell apoptosis, suggests an
important role for this protein in the mechanism of glucose
toxicity. UCP-2 has potential as a pharmaceutical target in
the prevention and treatment of L-cell failure in diabetes.
Fig. 3. Glucose induction of UCP-2. 24 h incubation with 5.5
(n = 5), 11 (n = 3), or 22 (n = 5) mmol/l glucose causes a dose-depen-
dent increase in UCP-2 mRNA measured by semi-quantitative
RT-PCR (data shown as mean UCP-2/actin mRNA band density
ratio þ S.E.M.). A representative RT-PCR gel is shown (one of ¢ve
similar results). 11 mmol/l glucose was only tested in three of ¢ve
batches due to limitations of islet supply.
Fig. 4. Glucose induction of UCP-2 is not fully reversible. The 24 h
increase in UCP-2 mRNA expression induced by 22 mmol/l glucose
is not fully reversed when islets subsequently incubated in 5.5
mmol/l glucose for a further 24 h. Data shown are representative of
two similar results.
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